| 產(chǎn)品編號 | BIO0699SM |
| 英文名稱 | Anti-human LIV-1 / SLC39A6 (Ladiratuzumab Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應 | Human |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.1 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Human LIV1 HEK293 cells were stained with Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC220=0.06904 ug/mL.
Immobilized human LIV 1 His at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb), EC50=0.005145 ug/mL.
The purity of Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) is 98.2%, determined by SEC-HPLC.
Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
